自然流产的处理和不规范治疗

尹学敬; 杨慧霞

doi:10.19538/j.fk2026080103

PDF(895 KB)

中国实用妇科与产科杂志 ›› 2026, Vol. 42 ›› Issue (8) : 781-784. DOI: 10.19538/j.fk2026080103

专题笔谈

自然流产的处理和不规范治疗

尹学敬 ¹^,² ,
杨慧霞 ¹

作者信息 +

Management of spontaneous abortion and non-standard treatments

YIN Xue-jing ¹^,² ,
YANG Hui-xia ¹

Author information +

文章历史 +

摘要

自然流产是育龄女性常见的妊娠并发症，不仅严重损害女性生殖健康，而且亦会给患者及家属带来沉重心理及经济负担。现阶段国内各级医疗机构在先兆流产、复发性流产（recurrent spontaneous abortion，RSA）诊疗过程中普遍存在检查无针对性、用药指征不明确、多药叠加滥用等乱象，尤以孕激素类保胎药物、低分子量肝素（low molecular weight heparin，LMWH）等过度使用问题最为突出。文章针对临床上治疗先兆流产的现实情况，剖析激素、抗凝药物滥用的临床现象、产生根源，并梳理近年来国内外关于自然流产的专家共识及临床诊疗指南，基于循证医学及临床实践系统归纳自然流产规范化诊疗方案，旨在规范临床诊疗行为，遏制过度保胎与过度医疗，为临床实践提供参考。

Abstract

Spontaneous abortion is a common pregnancy complication among women of childbearing age，which not only seriously impairs women's reproductive health，but also imposes heavy psychological and economic burdens. At present，chaos such as non-targeted laboratory tests，unclear medication indications，and overuse of combined multiple medications commonly exist in the diagnosis and treatment of threatened abortion and recurrent spontaneous abortion in various medical institutions all over China，especially the overuse of progesterone-based drugs and low molecular weight heparin. The clinical manifestations and underlying causes of the abuse of hormones and anticoagulants against the background of the current clinical reality in the treatment of threatened abortion are analyzed in this article， and the expert consensuses and clinical diagnosis and treatment guidelines for spontaneous abortion in China and abroad in recent years are sorted out. The standardized diagnosis and treatment regimens for spontaneous abortion are systematically summarized based on evidence-based medicine and clinical practice in order to standardize clinical diagnosis and treatment behaviors， curb excessive pregnancy preservation and overtreatment， and provide references for clinical practice.

导出引用

尹学敬, 杨慧霞. 自然流产的处理和不规范治疗[J]. 中国实用妇科与产科杂志. 2026, 42(8): 781-784 https://doi.org/10.19538/j.fk2026080103

YIN Xue-jing, YANG Hui-xia. Management of spontaneous abortion and non-standard treatments[J]. Chinese Journal of Practical Gynecology and Obstetrics. 2026, 42(8): 781-784 https://doi.org/10.19538/j.fk2026080103

中图分类号： R714.21

参考文献

列表( 原文顺序 | 文献年度倒序 | 文中引用次数倒序 ) 可视化分析

[1]	自然流产诊治中国专家共识编写组. 自然流产诊治中国专家共识(2020年版)[J]. 中国实用妇科与产科杂志, 2020, 36(11):1082-1090. DOI:10.19538/j.fk2020110113. 本文引用 [1]

[2]

Royal College of Obstetricians and Gynaecologists. The investigation and treatment of couples with recurrent first trimester and second-trimester miscarriage(Green-top Guideline No.17)[EB/OL]. (2011-04-01)[2026-07-10]. https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_17.pdf.

https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_17.pdf

本文引用 [2]

[3]

Pylyp

, Spynenko

, Verhoglyad

, et al. Chromosomal abnormalities in products of conception of first-trimester miscarriages detected by Conventional cytogenetic analysis:a review of 1000 cases[J]. J Assist Reprod Genet, 2018, 35(2):265-271.DOI:10.1007/s10815-017-1069-1.

http://link.springer.com/10.1007/s10815-017-1069-1

本文引用 [1]

[4]	上海市医学会妊娠免疫专科分会, 全国卫生产业企业管理协会生殖免疫专业委员会, 复发性流产病因分级筛查临床实践中国专家共识编写组. 复发性流产病因分级筛查临床实践中国专家共识(2025年版)[J]. 中国实用妇科与产科杂志, 2025, 41(11):1111-1123. DOI:10.19538/j.fk2025110111. 本文引用 [2]

[5]	中国医师协会生殖医学专业委员会. 孕激素维持妊娠与黄体支持临床实践指南[J]. 中华生殖与避孕杂志, 2021, 41(2):95-105. DOI:10.3760/cma.j.cn101441-20200930-00543. 本文引用 [3]

[6]	高睿, 秦朗. 产科抗磷脂综合征的诊治原则与热点问题述评[J]. 四川大学学报(医学版), 2024, 55(3):513-520.DOI:10.12182/20240560104.

[7]	中华医学会妇产科学分会产科学组, 复发性流产诊治专家共识编写组. 复发性流产诊治专家共识(2022)[J]. 中华妇产科杂志, 2022, 54(9):653-667. DOI:10.3760/cma.j.cn112141-20220421-00259. 本文引用 [1]

[8]

Devreese

KMJ

, Bertolaccini

, Branch

, et al. An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome:guidance from the ISTH-SSC Subcommittee on lupus anticoagulant/antiphospholipid antibodies[J]. J Thromb Haemost, 2025, 23:731-744. DOI:10.1016/j.jtha.2024.10.022.

https://www.ncbi.nlm.nih.gov/pubmed/39510414

摘要

Antiphospholipid syndrome (APS) diagnosis is dependent on the accurate detection and interpretation of antiphospholipid antibodies (aPL). Lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and anti-beta2 glycoprotein I antibodies (aβ2GPI) remain the cornerstone of the laboratory part of APS diagnosis. In the 2023 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) APS classification criteria, the type of laboratory parameters remain essentially unchanged compared with the updated Sapporo classification criteria, and aCL and aβ2GPI measurement are still restricted to enzyme-linked immunosorbent assays (ELISAs) with moderate and high titer aPL thresholds defined as 40 and 80 Units, respectively, and a cutoff calculated by the 99th percentile has been abandoned. We must differentiate between classification criteria and assessment of aPL in clinical care. Classification criteria are strict and meant for participant inclusion in studies and trials to study homogeneous populations of patients. In contrast, laboratory detection for APS diagnosis in daily practice is broader, meant to diagnose each APS patient to optimize their management. Nowadays, there is increasing use of measurement of aPL by methods other than ELISAs, the semiquantitative reporting of titers is a matter of debate, as well as the role of the isotypes immunoglobulin (Ig)M and IgA, and the role of other aPL, such as antiphosphatidylserine (aPS)/prothrombin (PT) antibodies. Patients diagnosed with the disease may or may not fulfill the classification criteria, and inappropriate use of classification criteria may lead to mis(under)diagnosis. The aim of this guidance, based on literature and expert opinion, is to provide guidance recommendations for laboratory workers and clinicians on routine diagnostic assessment of patients with suspected APS.Copyright © 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.

[9]

Wang

, Hou

, Liu

, et al. Psychological changes among women with recurrent pregnancy loss during the COVID-19 period in northeastern China:a cross-sectional study[J]. Front Psychol, 2023, 14:1265926. DOI:10.3389/fpsyg.2023.1265926.

https://www.frontiersin.org/articles/10.3389/fpsyg.2023.1265926/full

本文引用 [1] 摘要

It aimed to investigate the prevalence of anxiety and depression in recurrent pregnancy loss (RPL) women and the related factors in Northeastern China during the Coronavirus disease 2019 (COVID-19) pandemic.

[10]

Bilardi

, Temple-Smith

. We know all too well the significant Psychological impact of miscarriage and recurrent miscarriage:So where is the support[J]. Fertil Steril, 2023, 120(5):937-939.DOI:10.1016/j.fertnstert.2023.08.951.

https://linkinghub.elsevier.com/retrieve/pii/S0015028223017181

本文引用 [1]

[11]	Practice Committee of the American Society for Reproductive Medicine. Recurrent pregnancy loss:a committee opinion[J]. Fertil Steril, 2026, 125(6):1023-1041. DOI:10.1016/j.fertnstert.2026.03.001. https://linkinghub.elsevier.com/retrieve/pii/S0015028226001275 本文引用 [4]

[12]	赵爱民, 李明阳. 不明原因复发性流产的诊治[J]. 中国实用妇科与产科杂志, 2025, 41(11):1060-1064.DOI:10.19538/j.fk2025110102. 本文引用 [1]

[13]	杨丽, 张弘. 难治性产科抗磷脂综合征的诊治[J]. 中国实用妇科与产科杂志, 2025, 41(11):1095-1099.DOI:10.19538/j.fk2025110109. 本文引用 [1]

[14]	ESHRE Guideline Group on RPL. ESHRE guideline:recurrent pregnancy loss:an update in 2022[J]. Hum Reprod Open, 2023, 2023(1):hoad002. DOI:10.1093/hropen/hoad002. 本文引用 [2]